Osteoporosis Prevention With Low Dose Alendronate

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The purpose of this study is to evaluate the efficacy of the intermittent administration of alendronate in a low dose, 70 mg once every two week, as osteoporosis prevention for menopausal, osteopenic patients, who don\'t want or can\'t receive an oestrogenic substitution treatment.
Epistemonikos ID: 4051d947c0d0089d09f51e37c2df9240e02989a0
First added on: May 04, 2024